{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T12:18:17Z","timestamp":1784290697586,"version":"3.55.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,3,22]]},"DOI":"10.7759\/cureus.56733","type":"journal-article","created":{"date-parts":[[2024,3,22]],"date-time":"2024-03-22T17:38:21Z","timestamp":1711129101000},"source":"Crossref","is-referenced-by-count":2,"title":["The Safety and Effectiveness of Bevacizumab in Metastatic Colorectal Cancer With Unresectable Metastases: A Real-Life Study From the South of Morocco"],"prefix":"10.7759","author":[{"given":"Ghizlane","family":"Rais","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farah","family":"Boutaagount","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rania","family":"Mokfi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meryem","family":"Maskrout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soundous","family":"Bennour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaymae","family":"Senoussi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fadoua","family":"Rais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laila","family":"Lahlou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung H","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021, 71:209-49. 10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"key":"ref2","unstructured":"Registre du Grand Casablanca 2013-2017. (2017). Accessed. March 4, 2024: https:\/\/contrelecancer.ma\/."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.10.003","article-title":"Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Cervantes A","year":"2023","unstructured":"Cervantes A, Adam R, Rosell\u00f3 S, et al.. Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023, 34:10-32. 10.1016\/j.annonc.2022.10.003","journal-title":"Ann Oncol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v29.i10.1569","article-title":"Systemic treatment for metastatic colorectal cancer","volume":"29","author":"Leowattana W","year":"2023","unstructured":"Leowattana W, Leowattana P, Leowattana T. Systemic treatment for metastatic colorectal cancer. World J Gastroenterol. 2023, 29:1569-88. 10.3748\/wjg.v29.i10.1569","journal-title":"World J Gastroenterol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2017.01.026","article-title":"The role of bevacizumab in solid tumours: a literature based meta-analysis of randomised trials","volume":"75","author":"Roviello G","year":"2017","unstructured":"Roviello G, Bachelot T, Hudis CA, Curigliano G, Reynolds AR, Petrioli R, Generali D. The role of bevacizumab in solid tumours: a literature based meta-analysis of randomised trials. Eur J Cancer. 2017, 75:245-58. 10.1016\/j.ejca.2017.01.026","journal-title":"Eur J Cancer"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005392.pub3","article-title":"Anti-angiogenic therapies for metastatic colorectal cancer","author":"Wagner AD","year":"2009","unstructured":"Wagner AD, Arnold D, Grothey AA, Haerting J, Unverzagt S. Anti-angiogenic therapies for metastatic colorectal cancer. Cochrane Database Syst Rev. 2009, CD005392. 10.1002\/14651858.CD005392.pub3","journal-title":"Cochrane Database Syst Rev"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2018.10.009","article-title":"Efficacy of bevacizumab in first-line treatment of metastatic colorectal cancer: a systematic review and meta-analysis","volume":"106","author":"Baraniskin A","year":"2019","unstructured":"Baraniskin A, Buchberger B, Pox C, Graeven U, Holch JW, Schmiegel W, Heinemann V. Efficacy of bevacizumab in first-line treatment of metastatic colorectal cancer: a systematic review and meta-analysis. Eur J Cancer. 2019, 106:37-44. 10.1016\/j.ejca.2018.10.009","journal-title":"Eur J Cancer"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2013-0107","article-title":"Efficacy and safety of bevacizumab in metastatic colorectal cancer: pooled analysis from seven randomized controlled trials","volume":"18","author":"Hurwitz HI","year":"2013","unstructured":"Hurwitz HI, Tebbutt NC, Kabbinavar F, et al.. Efficacy and safety of bevacizumab in metastatic colorectal cancer: pooled analysis from seven randomized controlled trials. Oncologist. 2013, 18:1004-12. 10.1634\/theoncologist.2013-0107","journal-title":"Oncologist"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.12892\/ejgo4011.2018","article-title":"Feasibility and tolerability of bevacizumab: a retrospective study in Japanese ovarian cancer patients","volume":"39","author":"Chikazawa K","year":"2018","unstructured":"Chikazawa K, Netsu S, Akashi K, Suzuki Y, Hotta D, Konno R. Feasibility and tolerability of bevacizumab: a retrospective study in Japanese ovarian cancer patients. Eur J Gynaecol Oncol. 2018, 39:790-4. 10.12892\/ejgo4011.2018","journal-title":"Eur J Gynaecol Oncol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-12-89","article-title":"Addition of bevacizumab to first-line chemotherapy in advanced colorectal cancer: a systematic review and meta-analysis, with emphasis on chemotherapy subgroups","volume":"12","author":"Macedo LT","year":"2012","unstructured":"Macedo LT, da Costa Lima AB, Sasse AD. Addition of bevacizumab to first-line chemotherapy in advanced colorectal cancer: a systematic review and meta-analysis, with emphasis on chemotherapy subgroups. BMC Cancer. 2012, 12:89. 10.1186\/1471-2407-12-89","journal-title":"BMC Cancer"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-011-0720-z","article-title":"Targeted therapy with bevacizumab (Avastin) for metastatic colorectal cancer","volume":"13","author":"Koukourakis GV","year":"2011","unstructured":"Koukourakis GV, Sotiropoulou-Lontou A. Targeted therapy with bevacizumab (Avastin) for metastatic colorectal cancer. Clin Transl Oncol. 2011, 13:710-4. 10.1007\/s12094-011-0720-z","journal-title":"Clin Transl Oncol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-021-08398-z","article-title":"Metastatic colo-rectal cancer: real life experience from an Indian tertiary care center","volume":"21","author":"Sharma V","year":"2021","unstructured":"Sharma V, Sharma A, Raina V, et al.. Metastatic colo-rectal cancer: real life experience from an Indian tertiary care center. BMC Cancer. 2021, 21:630. 10.1186\/s12885-021-08398-z","journal-title":"BMC Cancer"},{"key":"ref13","article-title":"Colorectal cancer: epidemiology, risk factors, and protective factors","author":"Macrae FA","year":"2024","unstructured":"Macrae FA. Colorectal cancer: epidemiology, risk factors, and protective factors. UpToDate. Shah SM (ed): Wolters Kluwer, Philadelphia, PA; 2024."},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.5114\/wo.2022.114678","article-title":"Bevacizumab in metastatic colorectal cancer in a real-life setting - toxicity profile, survival outcomes, and impact of tumor sidedness","volume":"26","author":"Chibani H","year":"2022","unstructured":"Chibani H, El Bairi K, Al Jarroudi O, Afqir S. Bevacizumab in metastatic colorectal cancer in a real-life setting - toxicity profile, survival outcomes, and impact of tumor sidedness. Contemp Oncol (Pozn). 2022, 26:32-9. 10.5114\/wo.2022.114678","journal-title":"Contemp Oncol (Pozn)"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.14740\/gr1062w","article-title":"Difference between left-sided and right-sided colorectal cancer: a focused review of literature","volume":"11","author":"Baran B","year":"2018","unstructured":"Baran B, Mert Ozupek N, Yerli Tetik N, Acar E, Bekcioglu O, Baskin Y. Difference between left-sided and right-sided colorectal cancer: a focused review of literature. Gastroenterology Res. 2018, 11:264-73. 10.14740\/gr1062w","journal-title":"Gastroenterology Res"},{"key":"ref16","article-title":"Pathology and prognostic determinants of colorectal cancer","author":"Compton CC","year":"2023","unstructured":"Compton CC. Pathology and prognostic determinants of colorectal cancer. UpToDate. Shah SM (ed): Wolters Kluwer, Philadelphia, PA; 2023."},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/7407190","article-title":"Mechanisms of metastasis in colorectal cancer and metastatic organotropism: hematogenous versus peritoneal spread","volume":"2019","author":"Pretzsch E","year":"2019","unstructured":"Pretzsch E, B\u00f6sch F, Neumann J, et al.. Mechanisms of metastasis in colorectal cancer and metastatic organotropism: hematogenous versus peritoneal spread. J Oncol. 2019, 2019:7407190. 10.1155\/2019\/7407190","journal-title":"J Oncol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt591","article-title":"Metastatic pattern in colorectal cancer is strongly influenced by histological subtype","volume":"25","author":"Hugen N","year":"2014","unstructured":"Hugen N, van de Velde CJ, de Wilt JH, Nagtegaal ID. Metastatic pattern in colorectal cancer is strongly influenced by histological subtype. Ann Oncol. 2014, 25:651-7. 10.1093\/annonc\/mdt591","journal-title":"Ann Oncol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.07.113","article-title":"Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale","volume":"23","author":"Colucci G","year":"2005","unstructured":"Colucci G, Gebbia V, Paoletti G, et al.. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. J Clin Oncol. 2005, 23:4866-75. 10.1200\/JCO.2005.07.113","journal-title":"J Clin Oncol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-017-3360-z","article-title":"TRIBE-2: a phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group","volume":"17","author":"Cremolini C","year":"2017","unstructured":"Cremolini C, Marmorino F, Loupakis F, et al.. TRIBE-2: a phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group. BMC Cancer. 2017, 17:408. 10.1186\/s12885-017-3360-z","journal-title":"BMC Cancer"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70154-2","article-title":"Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial","volume":"14","author":"Cunningham D","year":"2013","unstructured":"Cunningham D, Lang I, Marcuello E, et al.. Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial. Lancet Oncol. 2013, 14:1077-85. 10.1016\/S1470-2045(13)70154-2","journal-title":"Lancet Oncol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.clcc.2019.07.003","article-title":"ACORN: observational study of bevacizumab in combination with first-line chemotherapy for treatment of metastatic colorectal cancer in the UK","volume":"18","author":"Khakoo S","year":"2019","unstructured":"Khakoo S, Chau I, Pedley I, et al.. ACORN: observational study of bevacizumab in combination with first-line chemotherapy for treatment of metastatic colorectal cancer in the UK. Clin Colorectal Cancer. 2019, 18:280-91.e5. 10.1016\/j.clcc.2019.07.003","journal-title":"Clin Colorectal Cancer"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.3390\/medicina59020350","article-title":"Bevacizumab treatment for metastatic colorectal cancer in real-world clinical practice","volume":"59","author":"Dinu IM","year":"2023","unstructured":"Dinu IM, Mih\u0103il\u0103 M, Diculescu MM, et al.. Bevacizumab treatment for metastatic colorectal cancer in real-world clinical practice. Medicina (Kaunas). 2023, 59:350. 10.3390\/medicina59020350","journal-title":"Medicina (Kaunas)"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1159\/000320222","article-title":"Clinical outcomes in elderly patients with metastatic colorectal cancer receiving bevacizumab and chemotherapy: results from the BRiTE observational cohort study","volume":"78","author":"Kozloff MF","year":"2010","unstructured":"Kozloff MF, Berlin J, Flynn PJ, et al.. Clinical outcomes in elderly patients with metastatic colorectal cancer receiving bevacizumab and chemotherapy: results from the BRiTE observational cohort study. Oncology. 2010, 78:329-39. 10.1159\/000320222","journal-title":"Oncology"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdp233","article-title":"Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study","volume":"20","author":"Van Cutsem E","year":"2009","unstructured":"Van Cutsem E, Rivera F, Berry S, et al.. Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann Oncol. 2009, 20:1842-7. 10.1093\/annonc\/mdp233","journal-title":"Ann Oncol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-56528-2","article-title":"Bevacizumab improves survival in metastatic colorectal cancer patients with primary tumor resection: a meta-analysis","volume":"9","author":"Cao D","year":"2019","unstructured":"Cao D, Zheng Y, Xu H, Ge W, Xu X. Bevacizumab improves survival in metastatic colorectal cancer patients with primary tumor resection: a meta-analysis. Sci Rep. 2019, 9:20326. 10.1038\/s41598-019-56528-2","journal-title":"Sci Rep"},{"key":"ref27","article-title":"Safety and tolerability of first-line bevacizumab in metastatic colorectal cancer","volume":"17","author":"Akun E","year":"2012","unstructured":"Akun E, Okutur K, Seber S, et al.. Safety and tolerability of first-line bevacizumab in metastatic colorectal cancer. J BUON. 2012, 17:669-76.","journal-title":"J BUON"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/238335-the-safety-and-effectiveness-of-bevacizumab-in-metastatic-colorectal-cancer-with-unresectable-metastases-a-real-life-study-from-the-south-of-morocco","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,22]],"date-time":"2024-03-22T17:38:27Z","timestamp":1711129107000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/238335-the-safety-and-effectiveness-of-bevacizumab-in-metastatic-colorectal-cancer-with-unresectable-metastases-a-real-life-study-from-the-south-of-morocco"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,22]]},"references-count":27,"URL":"https:\/\/doi.org\/10.7759\/cureus.56733","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3910738\/v1","asserted-by":"object"}]},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3,22]]}}}